<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To determine the prevalence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and other immunologic abnormalities in patients with occlusive <z:chebi fb="46" ids="15035">retinal</z:chebi> vascular events, exempt from conventional risk factors of <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Forty patients with <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:e sem="disease" ids="C1096458" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">vascular occlusion</z:e> (26 with <z:chebi fb="46" ids="15035">retinal</z:chebi> vein occlusions, eight with <z:mp ids='MP_0006134'>arterial occlusions</z:mp>, two with combined venous and <z:mp ids='MP_0006134'>arterial occlusions</z:mp>, and four with venous occlusions plus <z:hpo ids='HP_0002633'>vasculitis</z:hpo>), free of main accepted risk factors for <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:mp ids='MP_0005048'>thrombosis</z:mp>, were prospectively screened for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (anticardiolipin-antibodies and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>) and other immunologic abnormalities </plain></SENT>
<SENT sid="2" pm="."><plain>Fourteen patients were younger than 50 years </plain></SENT>
<SENT sid="3" pm="."><plain>Prevalence and mean values of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) were compared with those in a homogeneous control group of 40 patients </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The prevalence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> in the study group was 22.5% (nine of 40) </plain></SENT>
<SENT sid="5" pm="."><plain>Comparison with control group prevalence (5% [two of 40]) showed a statistically significant difference (P = .04) </plain></SENT>
<SENT sid="6" pm="."><plain>Six patients in the study group disclosed positivity for IgG-anticardiolipin antibodies, one patient for IgM anticardiolipin antibodies, and two patients for both isotypes IgG and IgM anticardiolipin antibodies </plain></SENT>
<SENT sid="7" pm="."><plain>The antibody assay for <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> was negative for <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="8" pm="."><plain>Three patients were diagnosed as having primary <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome and are undergoing systemic <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Relevant immunologic abnormalities were also found (27.5% with <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo>, 35% with elevation of circulating immune complexes, 35% with <z:hpo ids='HP_0004431'>complement deficiency</z:hpo>, 30% with positive rheumatoid factor, and 17.5% with positive C-reactive protein) </plain></SENT>
<SENT sid="10" pm="."><plain>Thirteen patients (32.5%) had more than four parameters altered </plain></SENT>
<SENT sid="11" pm="."><plain>No significant association was found between prevalence or mean values of anticardiolipin antibody and patients younger than 50 years </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The high prevalence of anticardiolipin antibodies in patients with vaso-occlusive <z:hpo ids='HP_0000488'>retinopathy</z:hpo> exempt from conventional risk factors, and the relevant diagnostic and therapeutic implications, lead us to recommend a systematic search for specific <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> in such patients </plain></SENT>
</text></document>